CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Jakavi for myelofibrosis

Project Number PC0012-000
Brand Name Jakavi
Generic Name Ruxolitinib
Strength 5mg, 15mg, and 20mg
Tumour Type Other
Indication Myelofibrosis
Funding Request For the treatment of patients with myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.
Review Status Complete
Pre Noc Submission No
NOC Date June 19, 2012
Manufacturer Novartis Pharmaceuticals Canada Inc.
Sponsor Novartis Pharmaceuticals Canada Inc.
Submission Date June 25, 2012
Submission Deemed Complete July 3, 2012
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ July 10, 2012
Check-point meeting August 15, 2012
pERC Meeting October 18, 2012
Initial Recommendation Issued November 1, 2012
Feedback Deadline ‡ November 16, 2012
pERC Reconsideration Meeting December 20, 2012
Final Recommendation Issued January 14, 2013
Notification to Implement Issued January 29, 2013
Therapeutic Area Myelofibrosis
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.